Floatz logo

Therapeutic Asset Ratings

9,920 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Navitoclax
Myelofibrosis
Jacqueline Garcia, MDP1CC (43)
Navitoclax
Myeloid Neoplasm
Jacqueline Garcia, MDP1CC (43)
Navitoclax
Myeloproliferative Neoplasm
Jacqueline Garcia, MDP1CC (43)
Navitoclax
Ovarian Cancer
Sunnybrook Health Sciences CentreP1CC (43)
Navitoclax
Triple-Negative Breast Carcinoma
Sunnybrook Health Sciences CentreP1CC (43)
nc525
Acute Myeloid Leukemia
NextCure, Inc.P1CC (43)
nc525
Chronic Myelomonocytic Leukemia
NextCure, Inc.P1CC (43)
Ncp-Cd47 Sirna Intratumorally
Metastatic Neoplasm
West China HospitalP1CC (43)
Neldaleucel
Non-Hodgkin Lymphoma
Marker Therapeutics, Inc.P1CC (43)
Nelitolimod
Pancreatic Adenocarcinoma
TriSalus Life Sciences, Inc.P1CC (43)
Neoantigen Personalized Cancer Vaccine
Digestive System Neoplasm
Ruijin HospitalP1CC (43)
Neoantigen Personalized Cancer Vaccine
Neoplasm
Ruijin HospitalP1CC (43)
Neovax
Lymphoid Leukemia
Dana-Farber Cancer InstituteP1CC (43)
Neratinib
Amyotrophic Lateral Sclerosis Type 19
M.D. Anderson Cancer CenterP1CC (43)
Neratinib
Ovarian Cancer
Virginia Commonwealth UniversityP1CC (43)
Neratinib
Refractory Malignant Neoplasm
OHSU Knight Cancer InstituteP1CC (43)
Neural Stem Cells-Expressing Crad-S-Pk7
Glioblastoma
City of Hope Medical CenterP1CC (43)
Neurotop
Isolated Focal Cortical Dysplasia
GRIN Therapeutics, Inc.P1CC (43)
Neurotop
Nervous System Disorder
GRIN Therapeutics, Inc.P1CC (43)
ngm438
Bladder Transitional Cell Carcinoma
NGM Biopharmaceuticals, IncP1CC (43)
ngm438
Endocervical Carcinoma
NGM Biopharmaceuticals, IncP1CC (43)
ngm831
Bladder Transitional Cell Carcinoma
NGM Biopharmaceuticals, IncP1CC (43)
ngm831
Endocervical Carcinoma
NGM Biopharmaceuticals, IncP1CC (43)
Niclosamide
Acute Myeloid Leukemia
Stanford UniversityP1CC (43)
Nintedanib
Acute Myeloid Leukemia With 11q23 Abnormalities
Northwestern UniversityP1CC (43)
Showing 3451 to 3475 of 9,920 assets
PreviousPage 139 of 397Next